Meeting
2013 Genitourinary Cancers Symposium
Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States.
Authors
Nicholas J. Vogelzang
US Oncology Research/Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Nicholas J. Vogelzang , James E. Signorovitch , Peggy L. Lin , Zhimei Liu , Kenneth W. Culver , Jeffrey A. Scott , Sumanta Kumar Pal , Eric Jonasch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 418)
DOI
10.1200/jco.2013.31.6_suppl.418
Abstract #
418
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
First Author: Lothar Mueller
Poster
2013 Genitourinary Cancers Symposium
Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States.
First Author: Sumanta Kumar Pal
Poster
2012 Genitourinary Cancers Symposium
Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).
First Author: Michael Roger Harrison
Poster
2016 Genitourinary Cancers Symposium
Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Trang H. Au